AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 13, 2026 ARK reports its September 30 Beam Therapeutics position Headline · Source: SEC filing
Nasdaq: $BEAMPrecision genetic medicinesBEACON pivotal topline reportedRisto-cel remains investigational

BEAM Stock Hub: Beam Therapeutics News, Risto-cel and Cash Runway

Beam is closer to its first U.S. application after the BEACON study met its primary efficacy endpoint in the November 10 topline. The company ended September with $1.044 billion in cash and marketable securities, but part of the funding behind its mid-2029 runway forecast depends on regulatory progress. The question is whether risto-cel can move toward a launch without slowing the pivotal lung-disease cohort for BEAM-302.

Last updated: November 21, 2026Financial period: quarter and nine months ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Beam Therapeutics ($BEAM), research updated November 21, 2026
22 pages covering BEACON, the pivotal BEAM-302 cohort, September financial results, conditional credit, equity dilution, scenarios and FAQ. For personal use only: redistribution prohibited.
Get the report (PDF)
Next clinical catalyst
December 12, 2026 · BEACON oral presentation at ASH

Abstract 335 covers risto-cel efficacy, safety, and patient-reported outcomes from an earlier cutoff than the November pivotal topline. Beam’s December 2 Evercore investor conference comes first; the company has no announced date for submitting the risto-cel application. ASH presentation announcement.

Completed: November 10 BEACON topline. Detailed pivotal results are planned for a separate medical meeting in 2027.
Beam Therapeutics BEAM daily stock chart
Daily chart $BEAM. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

BEAM stock at a glance

Chart analysis · JC
Technical chart analysis of $BEAM with bull and bear scenarios on JC Just Charts.
Cash and securities · Sep 30
$1,043.873M
September balance sheet; excludes restricted cash.
Revenue · Q3 2026
$0.307M
Net loss · Q3 2026
$134.405M
Loss per share of $1.28.
Operating cash use · 9M 2026
$305.357M
Common shares · Oct 27
103.50M
10-Q cover count; see share dilution for awards.
Short interest · Oct 30
26.08M
Nasdaq settlement data; 13.7 days to cover.

Where Beam Therapeutics stands now

Risto-cel has crossed a threshold in evidence, but not yet a regulatory threshold. For shareholders, a timely filing matters because it would put a clinical asset into a formal regulatory process and give the company’s financing assumptions a more concrete test. For patients and treatment centers, the detailed evidence still has to show who benefited, for how long, and with what treatment burden.

The financing risk: A later filing would matter twice. It would postpone the possibility of a launch and could also affect the timing or availability of debt management expects to draw under specified conditions. See the facility terms.

What has improved

Beam can prepare the risto-cel filing around an announced pivotal endpoint result while continuing to enroll its lead liver study.

What remains open

The pivotal response rate and detailed safety tables have yet to be presented, and the runway projection assumes conditional financing.

Latest BEAM news

Nov 13, 2026

ARK reports its September 30 Beam Therapeutics position

ARK Investment Management reported beneficial ownership of 11,805,372 Beam shares, or 11.43%, as of September 30, 2026. The earlier June 30 position was 10,234,862 shares, or 9.95%.

Nov 10, 2026

Beam Therapeutics Announces Positive Topline Pivotal Risto-cel Data in Sickle Cell Disease

BEACON Phase 1/2 study of risto-cel achieved its primary efficacy endpoint of freedom from severe VOCs for at least 12 consecutive months, based on independently adjudicated results, and met all primary safety endpoints at the prespecified interim analysis. All secondary endpoints were also met. As of the October 20, 2026 data cutoff, 39 adults and 10 adolescents were treated, and 31 patients completed the follow-up period for the VF12 endpoint. Beam expects to submit a BLA to the FDA as early as the end of 2026.

Nov 4, 2026

Beam announces December 12 ASH oral presentation for risto-cel

Beam announced that ASH abstract 335 would report efficacy, safety and patient-reported outcomes from the Phase 1/2 BEACON study in adolescents and adults with sickle cell disease.

Nov 3, 2026

Beam Therapeutics reports September results and conditional cash runway

Beam reported $1,043.873 million of cash and marketable securities at September 30 and a $134.405 million net loss for the quarter. Its operating runway into mid-2029 assumes an additional $200 million of conditional borrowing.

Oct 28, 2026

FDA individualized-editing draft is sector context

The non-binding draft addresses individualized products and permits comments until November 27. It names no Beam program and does not approve a therapy or change a program’s existing path.

BEAM stock catalysts: dated events and company windows

Beam Therapeutics programs by stage of evidence

PIVOTAL TOPLINE

Risto-cel · sickle cell disease

The next inflection is the transition from an endpoint announcement to an application that the FDA can review. Read the BEACON analysis.

PIVOTAL COHORT ENROLLING

BEAM-302 · alpha-1 deficiency

The test is durable functional protein in a larger population. Lung and liver outcomes are separate questions. Read the AATD analysis.

EARLIER CLINICAL DEVELOPMENT

BEAM-301 and BEAM-304

The metabolic programs need bigger clinical datasets before their potential can be related to a regulatory or commercial timeline. Read about GSDIa and PKU.

Beam Therapeutics deep dive: the full analysis

The essential distinction is between independent clinical programs and a shared financial plan. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios for Beam Therapeutics

The case for Beam rests on two different propositions. Risto-cel needs to turn evidence from patients with severe sickle cell disease into a U.S. product that treatment centers can actually deliver. BEAM-302 needs to turn a promising biomarker response into a regulatory package for alpha-1 antitrypsin deficiency. The two programs share a company and some corporate costs, but they do not share the same clinical endpoint, route to patients, or stage of evidence. September liquidity gives Beam time to pursue both. Some of the additional funding assumed in its runway forecast, however, depends on the earlier drug moving through the FDA.

Constructive case

The risto-cel application is submitted near the first window indicated by management and accepted on a timeline that allows Beam to qualify for the first regulatory loan draw. The detailed BEACON results give treatment centers a clear picture of the chance of durable relief, the burdens of treatment, and the populations studied. BEAM-302 proceeds through enrollment without the risto-cel filing consuming the resources it needs. The result is a company that can approach its first potential launch while preserving a second substantial clinical program.

Cautious case

Beam needs longer to assemble the filing or to satisfy a request during review. The cash cost of keeping clinical and commercial teams in place continues while the conditional debt remains unavailable. At the same time, longer follow-up on the liver program reveals greater variability than the earlier cohorts suggested. Capital remains available at the beginning of that sequence, but a longer gap to the next decisive event may force a narrower pipeline or additional financing.

Base case: progress with a gap between evidence and revenue

A submission is a credible near-term prospect after the November 10 BEACON announcement. It would still be premature to model a launch date or product revenue from a filing window. The base case gives the company credit for reaching the point at which an application is plausible, but keeps approval, payer access, and adoption outside the near-term financial base. It treats the BEAM-302 pivotal cohort as a separate source of potential value rather than a fallback that instantly replaces risto-cel if the FDA timetable slips.

The scenarios differ mainly in how long Beam has to fund both programs before it receives decisive information. A delay disclosed with a clear explanation and a finite next step has a different economic cost from a delay with no regulatory plan. On the other side, a punctual filing that leaves important questions about commercial access would improve the calendar without fully improving the business. The most useful distinction is what has actually become less uncertain: evidence, regulatory timing, access, or financing.

What would falsify this reading?

The analysis assumes that risto-cel can advance toward a filing without materially weakening Beam’s ability to run the pivotal AATD cohort. The calendar and the cash-flow statement provide separate ways to test that assumption.

  • A changed filing plan: a public delay accompanied by a requirement for new patient follow-up or a substantive addition to the filing package would weaken the assumption that the existing BEACON program can support the earliest submission window.
  • Uncertain follow-up: if the detailed BEACON data show that the headline is sensitive to who could be evaluated, or that serious complications limit the relevant population, the case for treatment-center adoption becomes narrower even if the study met its statistical objective.
  • Less durable clinical biology: if functional alpha-1 antitrypsin does not remain elevated across the pivotal group, early responses in selected participants would carry less weight. Longer follow-up should also clarify whether liver findings and respiratory measures move in the expected direction.
  • A different funding plan: if the next financial report shows materially higher spending or a shorter runway with no matching development progress, a large absolute balance would no longer support the same view of financing flexibility. A lasting improvement would be a stronger cash plan that relies less on a conditional draw.

02 What Beam Therapeutics does

Beam Therapeutics is a clinical-stage biotechnology company developing medicines for inherited diseases. Base editing, at the level that matters to a patient or shareholder, aims to change an individual DNA letter to produce a lasting therapeutic effect. For risto-cel, the clinical aim is to change the balance of hemoglobin produced by a patient’s blood cells so fewer red cells sickle and obstruct blood vessels. For the lead liver program, the aim is to improve production of a protective protein and reduce the burden of an abnormal form associated with liver disease. These goals arise from different disease biology and must be tested in different populations. Beam discusses the portfolio in its September Form 10-Q.

In blood disorders, the immediate commercial question is whether a patient can make it through a transplant-centered course of treatment. The result of an infusion depends on more than the treatment’s clinical activity: health before treatment, capacity at the transplant center, recovery time, and the support available after discharge matter. In Beam’s liver programs, the exposure from a one-time intervention calls for a different kind of follow-up. Investigators need to understand the durability of the response and evaluate delayed or infrequent safety findings in people with different degrees of organ disease. Success with one type of treatment would help establish the company as a developer of genetic medicines; it would not settle the relevant questions for the other programs.

Beam’s accounting reflects its stage of development. Its September financial statements report license and collaboration revenue, rather than commercial product sales. Contract events can produce revenue or cash well before a Beam product reaches the market, but those amounts say little about demand for a future approved medicine. Nor does a company-sponsored conference result describe the revenue opportunity. There is a long chain between an eligible patient, a physician’s recommendation, a treatment slot, coverage for the procedure, and completed treatment. Risto-cel is the first program where Beam may soon have to fund multiple parts of that chain at once.

The business has some ways to share risk. A license can leave a partner responsible for development, while preserving the possibility of milestone revenue for Beam. Internal programs give Beam more influence over priorities but require it to fund more of the work itself. These routes can coexist without giving the company interchangeable sources of cash: a company’s right to a contingent payment is quite different from the ability to decide when to fund another clinical cohort.

03 BEAM stock catalysts: a filing, a review, and a clinical update

The November 10 release changed the immediate question from whether Beam would report an endpoint result by year-end to what the company does with that result. Management expects a U.S. biologics license application, or BLA, for risto-cel as early as year-end 2026. That language sets the earliest company window and leaves the day open. As of November 21, Beam had not announced a submission. The next regulatory event to look for is a statement that the application has reached the FDA, rather than a restatement that the company is preparing it.

A submission, acceptance for filing, and approval have different consequences. A submission begins the agency’s initial assessment of the application; a notice of acceptance would signify that the agency will review it. Approval would establish the terms under which the product can be marketed in the United States and would be a separate decision. Beam’s loan gives the distinctions a direct financial effect: under the disclosed terms, the first delayed draw depends on timely acceptance, not simply on sending the application, and the second depends on timely approval. September Form 10-Q, Note 12.

The December 2 Evercore conference is a scheduled investor appearance. A date certain for a webcast is useful for hearing management’s description of progress, but it is not a date for the next dataset. The next scheduled clinical presentation is the December 12 ASH oral presentation, abstract 335. The company expects it to include an earlier BEACON data cutoff than the November pivotal topline, with initial patient-reported outcomes. An updated conference presentation can add context even when it does not contain the most recent cutoff. Beam plans to present detailed pivotal results at a medical meeting in 2027 and has not announced the date.

BEAM-302 has a different calendar. On November 3, Beam said it expected to complete dosing in the global pivotal cohort in the first half of 2027. That is a target for treating participants, not a target for completion of follow-up, publication of the primary analysis, or submission of an application. Starting with a dosing date and adding a study’s observation window can help explain why a clinical event takes time; it cannot produce a reliable public results date when the company has not named one. In early 2027, the BEAM-304 goal is a first treatment in a separate study, an operational step with substantially less evidence attached to it.

04 Risto-cel: what BEACON measured

Severe vaso-occlusive crises are among the most disruptive manifestations of sickle cell disease. A crisis is an acute episode in which impaired blood flow can cause severe pain and, in serious cases, organ injury. For someone who experiences repeated crises, an extended interval free from severe events has immediate value. It can mean fewer hospital encounters and less disruption of work, school, and family life. It is also narrower than a claim that all symptoms resolve: someone can remain free of protocol-defined severe crises while still living with chronic pain, fatigue, or organ damage from years of disease. BEACON trial record.

BEACON is an open-label, single-arm Phase 1/2 study. In Beam’s November 10 analysis, the primary efficacy endpoint was freedom from severe vaso-occlusive crises for at least 12 consecutive months, commonly shortened to VF12. The company’s November 10 account of a prespecified interim analysis said the primary efficacy endpoint was met on independently adjudicated results. It also reported that all primary safety endpoints and all secondary efficacy endpoints were met, including freedom from inpatient hospitalization for severe crises for at least 12 consecutive months. Independent adjudication concerns the classification of events. It does not make the trial randomized or supply an untreated comparison group.

The counts distinguish exposure from evaluability. At the October 20, 2026 cutoff, 39 adults and 10 adolescents had been treated, and 31 patients had completed the follow-up required for VF12. The release gave the eligible follow-up count and said the endpoint was met, without giving the number of responders or a confidence interval. Thirty-one is therefore a denominator for a stage of follow-up, not a count of people who remained crisis-free. When the full data are presented, it will matter how many people were eligible, how many reached the analysis point, how serious events were handled, and how much follow-up extends beyond the qualifying year.

The earlier, peer-reviewed report is a separate analysis of the same ongoing trial. Gupta et al., New England Journal of Medicine, 2026, described an unplanned interim analysis of 31 treated patients, using an August 6, 2025 cutoff. Mean follow-up was 6.6 months, with individual observations ranging from 0.3 to 20.4 months. Investigators reported rapid engraftment and sustained shifts toward fetal hemoglobin among patients with available measurements. The same paper reported grade 3 or higher adverse events in 27 patients, serious adverse events in 12, and one death from idiopathic pneumonia syndrome. A reader should carry the safety burden into any comparison of the clinical results, not set it aside because the blood results were encouraging. The two analyses’ identical counts of 31 describe different populations: treated in the publication, versus having completed required VF12 follow-up in the November topline.

Beam said the later safety findings were consistent with previous study data and the known effects of the surrounding treatment course and underlying disease. That is an attribution by the company, without a detailed new adverse-event table in the topline. For a prospective treatment center, the question is not just whether a specific event was attributed to the medicine. What also matters is the total burden a suitable patient faces from the point of entering treatment through engraftment, recovery, and long-term follow-up.

The December abstract is relevant because quality of life can tell a different story from counting only events that reach the threshold for severe crisis. Beam’s November 4 release described early improvements from baseline in patient-reported physical function, pain, fatigue, and other domains. In a small open-label study, participation and time since treatment can affect which questionnaires are returned. A useful presentation would clarify the number of patients with paired measurements, the periods represented, and whether improvements were similar across domains. Those questions can be answered without treating patient-reported outcomes as substitutes for the adjudicated endpoint.

05 Sickle cell care and the commercial comparison

Risto-cel would enter a setting in which clinicians already have options. In a randomized trial in adults with frequent painful crises, Charache et al., New England Journal of Medicine, 1995, found that hydroxyurea reduced the median annual crisis rate from 4.5 with placebo to 2.5. That is evidence for a standard disease-modifying treatment, not a numerical comparison with BEACON. Supportive care, transfusion in selected circumstances, and donor transplantation in suitable patients present different benefits, burdens, and eligibility constraints. The prospect of a one-time cell treatment is particularly relevant for people whose disease remains severe, but an expensive and intensive treatment course is a different decision from managing a chronic condition with ongoing care.

The FDA first approved Casgevy and Lyfgenia for sickle cell disease in December 2023. The July 1, 2026 supplemental approval extended the U.S. Casgevy indication to age two and older for sickle cell disease with recurrent vaso-occlusive crises and separately for transfusion-dependent beta thalassemia. The expanded age range matters competitively because Beam’s BEACON announcement covers adults and adolescents; a current competitor label cannot be inferred from its original approval, and Beam’s eventual label cannot be inferred from the existence of pediatric precedent. The FDA’s original announcement also described Lyfgenia’s boxed warning for hematologic malignancy. Product-specific warnings should not be transferred from one therapy to another.

In the clinical study of exagamglogene autotemcel, Frangoul et al., New England Journal of Medicine, 2024, reported that 29 of 30 people with sufficient follow-up were free from severe vaso-occlusive crises for at least 12 consecutive months; 44 had been treated. These are results from that study, whose population, timing, and handling of events should be read on their own terms. It would be inaccurate to compare the 29 responders from that paper to Beam’s 31 patients with required follow-up as if both were response counts. A head-to-head efficacy or safety advantage has not been demonstrated.

Patient experience is already part of the comparative landscape. Sharma et al., Blood Advances, published online in 2025, reported improvements across several quality-of-life domains after exa-cel. That is a reason to ask about the design and completeness of Beam’s quality-of-life data, not to set an assumed benefit from a competing product. While endpoints such as transfusion burden and time in the hospital can inform discussions at treatment centers, selective comparison of whichever measure looks strongest in each study is unlikely to predict which therapy a patient can access or ends up choosing.

If the FDA approves risto-cel, its initial commercial reach will depend on center participation, the logistics of a course of treatment, and coverage decisions that are made before a patient can undergo it. Referral networks have to identify eligible patients and help them navigate evaluation; transplant centers need capacity for both treatment and recovery. Patients may face travel, family-care, or time-off-work costs even when a payer covers the medical procedure. An analysis based on the estimated number of patients with sickle cell disease alone would miss each of those points of attrition. The investment question is whether the therapy can offer compelling clinical and practical reasons for an eligible patient to complete the course through a participating center.

06 BEAM-302: lung protection and liver disease are different tests

Alpha-1 antitrypsin deficiency can do damage on two fronts. Too little functional alpha-1 antitrypsin in circulation leaves the lung less protected, while abnormal protein accumulation in the liver can contribute to liver disease. The measures available to clinicians are different in those organs. A change in a blood protein is evidence about a mechanism of disease; a slower decline in lung tissue or less progression of liver fibrosis requires different observations. The BEAM-302 registry separates blood markers, respiratory outcomes, and safety rather than treating them as one composite of benefit.

Existing treatment illustrates that distinction. In the RAPID randomized trial of intravenous augmentation in people with severe deficiency and lung disease, Chapman et al., The Lancet, 2015, found a slower decline in CT-measured lung density at total lung capacity. The combined measure across two lung volumes did not achieve statistical significance. On the liver side, Strnad et al., New England Journal of Medicine, 2022, reported reductions in abnormal liver protein and signals of improvement in an early study of fazirsiran, a different investigational treatment. One study provides context for measuring lung tissue loss under augmentation; the other illustrates why direct liver evidence matters. Neither predicts the size of an effect from BEAM-302.

The September 8 ERS disclosure drew from people in an open-label Phase 1/2 study. Beam had treated 38 across the lung and liver portions as of August 17, 2026. The ERS analysis used an earlier cutoff, June 24, 2026, and reported results from 29 efficacy-evaluable participants from the single-treatment dose-escalation cohorts, excluding the multidose and expansion groups. Follow-up reached as long as 18 months for some participants, not for every participant. Beam reported sustained increases in functional alpha-1 antitrypsin and decreases in mutant Z-AAT, alongside other biomarker changes. It characterized the observed safety findings as consistent with the known risks of this class of treatment. The clinical picture will become clearer as a larger population has longer observation and reports events and outcomes by cohort.

The next study group looks more like a regulatory test. The 10-Q describes approximately 50 additional participants with lung disease, with or without liver disease, in the global pivotal expansion. Based on agency feedback, Beam intends to pursue an accelerated approval pathway using alpha-1 antitrypsin biomarkers over 12 months. The registered study lists mean total and functional protein in blood over a year, as well as longer-term measures including lung density and exacerbations. Accelerated approval is a possibility, not an assurance that the FDA will accept those findings, agree to an indication covering both organs, or approve on a particular schedule.

The details of that population matter to the eventual discussion of access. A study that starts with symptomatic lung disease can address the response in people screened for that condition, while leaving different levels of liver disease less evenly represented. For someone living with both problems, a compelling result would describe what changes over time, not just the direction of a pooled laboratory measure. In a disease that progresses over years, a one-year marker can be useful precisely because it arrives earlier than organ outcomes, but those later outcomes still matter for the durability of the commercial case.

07 BEAM-301 and BEAM-304: the early evidence

Neither early liver program should be measured against the regulatory clock for risto-cel. BEAM-301 has an initial clinical signal in glycogen storage disease type Ia, abbreviated GSDIa. BEAM-304 has a proposed first clinical population in phenylketonuria, or PKU. One program has patient data with important limitations; the other is preparing to ask whether an effect can be observed in people at all. At this stage, the amount of uncertainty that can be removed by the next milestone differs much more than the programs’ similar names suggest.

BEAM-301: time until hypoglycemia and burden of care

People with GSDIa have difficulty maintaining blood glucose while fasting. Standard nutrition management addresses the day-to-day danger of hypoglycemia, while care teams monitor longer-term complications, including in the liver and kidneys. Kishnani et al., Genetics in Medicine, 2014, describe the need for coordinated care and ongoing dietary management. Han et al., Nutrients, 2026, reported a small prospective observational comparison of conventional and extended-release cornstarch in hepatic glycogen storage disease. Both periods had comparable overall overnight glucose metrics in that study. Its relevance is the burden and variability of dietary management; it is not evidence from BEAM-301 patients or a comparator arm for Beam’s study.

Beam’s October 27 company report described six treated adults from a Phase 1/2 study with an August 17, 2026 cutoff, with median follow-up of 7.6 months. Two of three patients in the higher of the two reported groups reached the protocol-defined ceiling of 15 hours in a controlled fasting assessment and were no longer using starch supplementation, according to the company. Beam also reported serious treatment-emergent adverse events considered related to BEAM-301 in four of the six patients, including three Grade 3 infusion-related reactions. No Grade 4 or 5 treatment-emergent adverse events, dose-limiting toxicities, or treatment discontinuations due to an adverse event were reported in that update. A ceiling means the test stopped at that duration; it is not a reading of the longest interval either participant might sustain in daily life. A six-person, open-label study cannot tell a family how likely those results are across the eligible population or how long the effect will last.

The registered study prioritizes safety and tolerability; fasting performance and supplement use are secondary clinical measures. An earlier company abstract used a June cutoff, when one participant in the higher group was not yet evaluable for efficacy. Beam moved to enroll a higher-dose cohort and said it plans to engage the FDA on a potential path. Neither enrollment in that cohort nor a planned discussion establishes a registration strategy. Reproducible fasting results, consistent day-to-day glucose control, and evidence across a larger number of patients would make the initial signal more informative.

BEAM-304: a trial start is its own milestone

PKU is an inherited condition in which phenylalanine can accumulate and harm neurological health. Clinical care aims to manage those levels over time, often with substantial dietary effort. Longo et al., Genetics in Medicine, 2019, discuss clinical considerations for pegvaliase in adults with PKU, including monitoring and the continuing role of dietary management. That published experience provides context for what blood phenylalanine means to patients and clinicians. It does not predict how adults with a specific variant will respond to Beam’s investigational treatment.

On November 3, Beam said initial Phase 1/2 evaluation would focus on patients with the R408W variant and examine safety, tolerability, and reduction in blood phenylalanine. The company targeted starting treatment in early 2027. Its estimate that an expanded program could potentially address up to half of U.S. patients with PKU describes the theoretical coverage of several approaches together, rather than the first cohort or a market forecast. First treatment would show that the program had entered the clinic. A repeatable change in blood phenylalanine with tolerable safety would be a later and more consequential step, and a clinically meaningful benefit across different patient populations would require further evidence.

BEAM-103 and future conditioning options

Beam’s November 3 quarterly filing said enrollment and dosing had been completed in its Phase 1 study of BEAM-103 in healthy volunteers. The company reported that treatment was well tolerated across the doses tested. The study is part of Beam’s ESCAPE strategy to explore alternatives to the intensive conditioning currently associated with stem-cell transplantation. This is early evidence in healthy volunteers. It does not show that patients with sickle cell disease can receive a BEAM treatment with less intensive conditioning, and it does not change the treatment burden in the current risto-cel program. BEAM-103 trial record.

08 BEAM earnings: the September quarter in context

Beam’s operating loss widened in the September quarter without a large change in total research and development expense. The Form 10-Q statements of operations and management discussion show why. License and collaboration revenue fell by $9.391 million, total operating expenses rose by $5.120 million, and operating loss widened by $14.511 million. Other income was $7.323 million lower than a year earlier. The two effects together increased the net loss by $21.834 million. There were no quarterly product sales to offset operating expense or show an early sales trajectory.

Condensed results (USD millions except per share)
Line itemQ3 2026Q3 20259M 20269M 2025
License and collaboration revenue0.3079.69832.53525.634
Research and development110.110109.769309.730310.343
General and administrative31.51926.74097.89581.539
Total operating expenses141.629136.509407.625391.882
Operating loss(141.322)(126.811)(375.090)(366.248)
Derivative fair-value change4.700(2.600)3.0001.900
Noncontrolling investments fair-value change(1.021)4.937(0.667)7.271
Contingent consideration fair-value change(2.856)1.000(2.547)0.945
Gain on sale of equity method investment——0.455—
Interest and other income, net6.09410.90323.44833.093
Total other income6.91714.24023.68943.209
Net loss(134.405)(112.571)(351.401)(323.039)
Basic and diluted loss per share (USD)(1.28)(1.10)(3.38)(3.31)

The relatively flat research total obscures changes in spending. Quarterly employee-related research costs rose from $27.636 million to $32.242 million, while external research and development expense fell from $33.487 million to $30.472 million. The 2025 quarter included a $14.507 million acquired in-process research expense that did not recur. Other research expense rose from $0.723 million to $16.615 million. Stable aggregate spending does not imply that individual clinical programs cost the same as in the prior year or that the next increment of spending will fall in the same category. Management discussion, quarterly R&D breakdown.

General and administrative costs moved more clearly upward. They were $4.779 million higher in the quarter and $16.356 million higher in the first nine months than in the corresponding periods of 2025. Expenses recorded as stock-based compensation fell to $18.555 million for the quarter and $56.877 million for nine months, from $22.747 million and $73.796 million. Compensation recognized in the income statement is an expense, but stock-based compensation is added back in the operating cash-flow reconciliation; it still matters to shareholders because it can translate into more shares over time. Neither a reduction in that noncash expense nor a gain in derivative fair value creates new cash available for clinical development. Note 10 and the cash-flow statement.

09 BEAM cash and operating runway

The relevant starting figure is $1,043.873 million of cash, cash equivalents, and marketable securities on September 30. The balance sheet and investment notes split that between $213.267 million of cash and equivalents and $830.606 million of current marketable securities; the $6.705 million of separately classified restricted cash was outside that figure. The investment portfolio included government securities, corporate notes, commercial paper, and a relatively small corporate equity component. That mix explains why the cash-and-securities figure is broader than cash in a bank account and changes when securities mature, are reinvested, or move in fair value.

Liquidity and capital position (USD millions)
Balance sheetSept. 30, 2026Dec. 31, 2025
Cash and equivalents213.267294.944
Marketable securities830.606950.266
Cash and securities combined1,043.8731,245.210
Restricted cash, separate6.7056.676
Total assets1,269.0721,481.177
Debt carrying amount100.364—
Lease liabilities, current and long-term143.508154.123
Total liabilities316.398242.819
Stockholders’ equity952.6741,238.358
Accumulated deficit(1,992.620)(1,641.219)

Having a substantial cushion is compatible with using it quickly. Operating activities used $305.357 million in the nine months ended September 30, compared with $261.813 million in the prior-year period. Purchases of property and equipment were $5.857 million, against $11.212 million a year earlier. The sum of operating cash use and capital purchases was therefore $311.214 million for nine months, about $34.58 million per month, a Merlintrader calculation using actual period totals. It is a backward-looking spending measure, before financing and the purchase and maturity of financial investments. Dividing the September liquid balance by that average gives about 30 months at unchanged spending, a sensitivity illustration rather than a forecast. Actual spending can change with the number of active studies, additional regulatory work, and eventual launch preparation.

Beam’s November 3 management forecast was that available resources would support planned operating expenses and capital expenditures into mid-2029. It included an additional $200 million expected from the Sixth Street facility, subject to conditions. The headline balance and runway answer two different questions. The first is a September measurement of liquid holdings; the second joins a spending plan to an expectation of future borrowing. Neither the simplified cash-flow sensitivity nor the company forecast is a calendar of payments. The most meaningful change would be new visibility on both the eligibility for the draws and how much Beam will need to spend before and after the regulatory decision.

The company describes expected funding coverage rather than identifying substantial doubt about its ability to continue as a going concern in the September quarterly report. That financial statement assessment has a different purpose and time horizon from a multi-year forecast. The current asset position does not imply self-funding operations. It gives Beam more ways to manage staggered clinical and regulatory timelines, while the accumulated deficit reflects the cost of years of development before a commercial product.

10 Sixth Street debt: what Beam can draw and when

On February 24, 2026, Beam closed its financing agreement with Sixth Street. The facility can reach $500 million, but the total includes five pieces with different conditions. The initial $100 million was funded at closing. September’s statement of financial position shows a long-term carrying amount of $100.364 million. Under Note 12, that balance comprises $100 million of original principal, a $4 million final payment fee, and a $3.636 million reduction for unamortized debt discount and issuance costs. The reported debt balance is neither the original cash receipt nor the amount that would be sufficient to repay the facility on any given day.

Sixth Street term facility as described in the September 10-Q
Financing componentUSD millionsStatus or trigger
Initial term loan100Funded at closing
Delayed Draw A100Timely FDA acceptance of the risto-cel application, subject to terms
Delayed Draw B100Optional draw on timely FDA approval, subject to terms
Sales milestone draw100Optional draw on reaching the contract’s risto-cel revenue target on time
Additional draw100Subject to agreement of Beam and the lenders

The loan matures on February 24, 2033. The rate can be based on three-month Secured Overnight Financing Rate (SOFR), with a 1% floor on that benchmark, plus 6.50 percentage points, or on the permitted base-rate alternative. At September 30, the effective rate was 10.6%. Interest is paid quarterly. There is no scheduled amortization during the term and principal is due at maturity. A 4% facility fee on original term-loan principal is payable at maturity or, when applicable, prepayment or acceleration. Prepayment premiums of 1% to 5% apply in certain cases, and specified transactions can trigger mandatory repayment. Financing optionality has a cost even when the equity share count stays the same.

The minimum-liquidity covenant applies under a condition tied to the company’s market capitalization. The covenant applies below the contract’s $1.75 billion threshold. When that condition applies, the minimum is $40 million before the first delayed draw, $80 million after Draw A, and $125 million after Draw B. These are floors under the agreement, not estimates of cash needed to operate. Negative covenants can constrain new debt, asset sales, and certain licensing transactions. The agreement permits up to $400 million in unsecured convertible notes subject to its terms; that permission is neither issued debt nor a committed source of money. Subject to certain exceptions, substantially all assets of Beam and its material subsidiaries, including intellectual property, secure the obligations on a first-priority basis. The September 10-Q also describes a commercially reasonable efforts obligation tied to risto-cel development and commercialization. Form 10-Q, Note 12 and liquidity discussion.

At September 30, the disclosed cash and securities exceeded funded loan principal by $943.873 million before considering lease liabilities, other obligations, or future spending, a Merlintrader calculation. That arithmetic shows why a conventional debt-to-earnings multiple is not the best lens for a company reporting operating losses. More useful questions are how much cash remains after the next year of development, whether funding triggers can be reached on time, and how easy it would be to license assets or raise additional capital under the covenants. Quarterly expense related to the debt was $2.722 million; nine-month expense was $6.395 million, distinct from $5.160 million of cash interest paid during that longer period.

11 Partnerships, contingencies, and the shape of cash flow

A collaboration can produce revenue without a product launch. The Lilly terms in Note 8 and the discussion of collaboration revenue describe a $200 million upfront payment from the 2023 agreement and up to $350 million of development-stage payments tied to contractual events. By September 30, Beam had received and recognized $50 million of milestones, including $25 million during the first nine months of 2026. Lilly contributed no revenue in the September quarter. A remaining potential payment depends on the underlying event; it is neither an account receivable simply because the deal exists, nor a dependable way to fund the next quarter’s expenses.

In the Apellis relationship, the obligation to provide research services ended on June 30, 2026. The 10-Q puts nine-month revenue from the agreement at about $7.2 million, with none in the third quarter. Biogen, which acquired Apellis, sent notice in September that the relevant FcRN-related rights would terminate effective in December. The revenue timing and the notice belong to different parts of that relationship. A conclusion that the earlier revenue would recur in every quarter would miss the service expiration. A conclusion that every partner-linked asset disappeared immediately would miss the effective date and the narrower scope of the notice.

Under the Pfizer license described in management’s discussion, Pfizer is responsible for developing the licensed candidate. Beam’s option to participate after Phase 1/2 would require a payment, and exercise would lead to a 35% Beam and 65% Pfizer sharing of net profits and specified development and commercialization costs. Allowing a partner to carry the work during clinical development limits Beam’s direct control over timing, while an eventual opt-in combines possible upside with future expense. Neither a milestone that depends on the partner nor a decision Beam has yet to make belongs in the same category as cash already held.

The Orbital transaction is a separate capital event. The 10-Q says Bristol Myers Squibb’s December 2025 acquisition of Orbital converted Beam’s shares into $255.1 million of cash at closing, with up to approximately $26.3 million more linked to potential escrow releases. Beam received another $0.5 million over the first nine months of 2026. The original closing amount belongs to 2025, and the possible balance is contingent. A cash reserve built partly from a transaction can support several years of work even though that same transaction cannot be counted on to support the next financing cycle.

On the obligation side, Note 7 describes a 2024 settlement with a research institution: $15 million upfront, paid that year, plus specified development, regulatory and commercial economics for BEAM-102 and BEAM-302. Beam paid the first $5 million development milestone in the September 2026 quarter. The agreement includes up to $15 million of development and regulatory milestones, up to $35 million in sales milestones per program, and a 1% net-sales royalty through 2038. Beam said the remaining milestones had not met the recognition criteria at September 30. The filing separately carried $4.7 million in derivative liabilities for Harvard and Broad success payments and $7.213 million in contingent consideration. Part II, Item 1 says Beam was not then subject to material legal proceedings; the disclosed settlement and intellectual-property risks are different facts from a pending material lawsuit.

The cash-flow statement shows the distinction between operating funding and portfolio administration. Nine-month investing cash provided was $117.251 million, primarily from $566.992 million in maturities exceeding $444.339 million of marketable-securities purchases. Purchases of property and equipment used $5.857 million and the sale of an equity method investment generated $0.455 million. The financing section contributed $106.458 million: $93.886 million of debt proceeds net of lender fees, less $0.813 million of issuance costs, plus $10.507 million from option exercises and $2.878 million from employee stock purchases. Against $305.357 million of operating use, cash and restricted cash fell $81.648 million to $219.972 million. A decline of that size in the cash subtotal is consistent with much larger operating use because maturities and financing offset part of the outflow. Form 10-Q, cash-flow statement.

12 BEAM share dilution: awards, warrants, and unused capacity

The September balance sheet showed 103,443,235 common shares issued and outstanding, against 101,748,962 at December 31, 2025, an increase of 1,694,273 shares, or about 1.67%, calculated from the two period-end balances. The cover page gives a later count of 103,495,644 on October 27. This is the ownership denominator for a dated comparison of outstanding shares, before taking account of instruments a holder may exercise. The third-quarter earnings calculation instead uses 104,698,517 weighted-average shares, including pre-funded warrants. Comparing that average with the October point-in-time count and treating the difference as new shares would conflate two different measures.

The 2025 public offering added 16,151,686 common shares at a contractual offering price of $28.48 and sold 1,404,988 pre-funded warrants at $28.47 apiece, with a residual exercise price of one cent. Aggregate net proceeds were about $470.5 million. Most of the financing value associated with those pre-funded instruments arrived at issuance, rather than awaiting exercise. The remaining exercise payment is small, but exercise increases the legal count of common shares. For loss per share, Beam treats the warrants as part of weighted-average shares because of the nominal exercise amount. The distinction helps explain why share counts in financial coverage can differ without contradicting each other. Notes 9 and 11.

Employee awards are a second category. Note 10 shows 12,732,619 options outstanding at September 30 at a weighted-average exercise price of $34.92, including 8,206,874 exercisable. The same note reports 3,825,844 unvested restricted awards. Together, the two lines were 16,558,463 potential shares excluded from diluted earnings per share because including them in a loss period would be antidilutive. That treatment is an accounting rule for the loss calculation, not a judgment that the underlying awards will never increase the share count. Vesting, forfeitures, and voluntary exercise ultimately determine what happens to each class. Under the employee stock purchase plan, issuance can add common shares through a separate channel.

The at-the-market program is an option to issue equity rather than a count of legal shares outstanding. Beam reports no stock sold under the Jefferies agreement in either the quarter or the nine months ended September 30. Historically the agreement generated $864.0 million of gross proceeds from 13,769,001 shares against a $1.1 billion maximum. That leaves about $236 million of indicated gross headroom by subtraction, not proceeds received and not a binding plan to issue a given number of shares. Future proceeds, shares issued, and commissions would depend on the terms and circumstances of actual issuance. MD&A, liquidity and capital resources.

There is a financing trade-off hidden by a simple share-count comparison. A loan can bridge the company toward regulatory progress without a common-share issuance, but it introduces interest, conditions, and repayment rights. A future equity issue could preserve cash flexibility and avoid borrowing costs, but it would spread the economic interest across additional shares. The amount and timing of financing matter as much as the type. Neither unused capacity nor an unexercised award should be presented as money already financing Beam’s operating plan.

13 Ownership, Form 4 activity, and trading liquidity

The November 13 Schedule 13G/A from ARK Investment Management reported 11,805,372 beneficially owned shares, or 11.43%, as of September 30. The August 14 amendment reported 10,234,862 shares and 9.95% as of June 30. That is a comparison between reporting dates, not a statement about daily trading activity in November. Separate reporting persons in a joint filing can report the same interest through different voting or disposition arrangements. Adding their reported totals would count the same beneficial position twice.

Farallon Capital Management’s August 13 Schedule 13G/A reported 10,282,210 beneficially owned shares, or 9.99%, as of June 30. The total included shares that could be acquired through warrants, so it should not be presented as an equal number of issued common shares already owned. Large reported positions show ownership concentration, but filings on different dates and with different instruments are not a current register of every share. There was no new Schedule 13D in the public filing sequence from August through November 21; the recent filings identified here are beneficial ownership statements under Schedule 13G.

Chief Executive Officer John Evans reported two transactions on each of October 15 and 16: an exercise for 25,000 shares and sales totaling 25,000 shares, under a Rule 10b5-1 plan adopted on June 16. The October 16 Form 4 uses M for the option exercise and S for the sale. The option reduction and related common-share acquisition on each day describe the same exercise. Senior Vice President of Finance Bethany Cavanagh reported a nondiscretionary sale of 187 shares on October 1 to cover tax withholding when awards vested; the filing uses S, rather than F. President Giuseppe Ciaramella’s September 25 Form 4 reported a gift of 123,407 shares to a trust on September 24, coded G. These examples differ from P for a purchase, A for a grant or award, and F for shares used to satisfy an exercise price or tax obligation in a transaction with the issuer. Motivation should not be inferred by pooling the codes. The September 10-Q separately disclosed adoption of a new plan that could permit Cavanagh to sell up to 25,904 shares, rather than reporting sales already made under that plan.

Beam’s stock is listed on the Nasdaq Global Select Market. Nasdaq’s October 30 settlement series showed 26,082,937 shares sold short and an average daily share volume of 1,904,581, equivalent to about 13.7 days of that average volume. October 15 had 26,243,605 shares short and average volume of 1,858,419. There is meaningful daily activity, but closing a large position in a short interval can still be difficult around new clinical or regulatory information. The quoted days-to-cover figure is the ratio of the reported position to a past volume average; it is not a deadline, and it can change as liquidity changes. Short interest measures open positions at settlement, not the number of short sales printed during a single session.

14 What would give Beam a durable commercial position?

Beam’s appointment of Eric Foster as chief commercial officer in September 2026 signals that management is assigning responsibility for a possible launch before regulatory approval. It does not reveal the economics of a future launch. The next meaningful commercial disclosures would show what is being built, how much it will cost to operate, and which barriers remain outside Beam’s control. A favorable FDA decision would improve the case, but it would still leave the company to translate interest among treatment centers into patients who finish the course of care.

Treatment supply, legal rights, and execution

A transplant-centered cell therapy has to reach a treatment center on a schedule that makes sense for an individual patient. Even if the product performs well after infusion, clinical and commercial teams have to coordinate supply, handoffs between organizations, and the long course of care that follows. Release of a treatment for use in a trial is a different test from reliably supplying an approved product at multiple centers. Beam’s quarterly risk disclosures describe manufacturing and supply risks and uncertainty about third-party intellectual-property claims. These concerns have practical consequences: interruptions can delay treatment, and contract restrictions or a dispute over rights can limit the flexibility to use an asset or share it with a partner.

For Beam, intellectual property has an economic role beyond the ability to pursue a product. The license success payments and settlement in Note 7 affect which part of a future economic benefit the company could retain. The secured credit agreement also affects which transactions it can complete with core assets. These obligations are relevant even without current material litigation; they link the value of a clinical program to the terms on which that value can be financed or shared. They should be considered alongside the costs of reaching a launch, rather than inferred from the size of the company’s cash holdings.

A first launch and a pivotal study can compete for capital even when they complement each other strategically. Hiring and contracting before approval may improve readiness, but costs can begin before the expected financial benefit. Deferring that work until approval preserves cash earlier at the risk of a slower start. Meanwhile, an ongoing study requires follow-up whether the commercialization outlook strengthens or weakens. For an investor trying to understand the business, the relevant disclosure is not how many programs are described as advancing. It is how much of the budget buys a reduction in a specific uncertainty, and whether the team can carry the remaining obligations without depending on financing that has not yet become available.

Published results for the next stage of BEACON, progress in FDA communications, and clearer information about funding eligibility would narrow the range of plausible outcomes for the business. Later evidence on organ-level outcomes for BEAM-302 would narrow a different uncertainty: whether a biomarker benefit translates into a lasting clinical result valuable to patients. Both would strengthen the company’s prospects, but for distinct reasons. Until those events occur, the financial statements describe a well-funded developer with substantial operating cash use; the trials describe potential therapies, not sales. The difference between those two descriptions is the opportunity Beam is trying to close.

Merlintrader Health Score · $BEAM

3.60out of 5
Balance sheet and runway · 30%4.0

September 30 cash and securities of $1,043.873 million give Beam time against $305.357 million of nine-month operating cash use. The mid-2029 forecast includes borrowing that depends on conditions.

Catalyst · 30%4.0

The November 10 pivotal topline supported the planned submission; no BLA date has been announced. The December 12 clinical presentation uses an earlier cutoff.

Dilution · 20%3.0

The September filing reported no 2026 year-to-date ATM issuance, but warrants, equity awards, and unused ATM capacity remain relevant to the share count.

Trading liquidity · 10%3.0

The September 10-Q lists Nasdaq Global Select Market, with no noncompliance notice announced as of November 21. The October 30 settlement showed around 1.9 million shares of average daily volume but short interest equivalent to 13.7 days of that volume.

Execution · 10%3.0

The November 3 program update showed progress across different stages of development; the company has yet to bring its first product through U.S. approval and into clinical practice.

Assessed November 21, 2026. Weighted calculation: 4.0 × 30% + 4.0 × 30% + 3.0 × 20% + 3.0 × 10% + 3.0 × 10% = 3.60 / 5. The score summarizes financial and operating resilience. It is not an investment recommendation or a probability of clinical success.

Red flags

  • Pivotal topline disclosure: the October BEACON follow-up group is known; the responder count and detailed safety tables are still to come.
  • Transplant burden: even a strong clinical effect would have to justify an intensive treatment course and compete for treatment-center capacity.
  • Funding tied to FDA steps: risto-cel submission alone does not unlock either regulatory draw cited in the facility.
  • Durability and safety: early BEAM-302 biomarker changes leave organ outcomes and longer-term safety to be demonstrated.
  • Nonrecurring funding: collaboration milestones and portfolio realizations have supported past cash balances but cannot be assumed to recur on a timetable Beam controls.
  • Equity exposure: a period of no ATM issuance does not retire the facility or the instruments that can add shares.

BEAM Stock FAQ: Beam Therapeutics Questions Answered

What is the next dated BEAM clinical catalyst?

As of November 21, 2026, Beam’s next clinical presentation is scheduled for December 12 at the ASH annual meeting. Abstract 335 will cover earlier BEACON risto-cel data; an investor appearance at Evercore on December 2 comes first. Company announcement.

Has Beam Therapeutics filed for FDA approval of risto-cel?

As of November 21, 2026, Beam had not announced a submission. Management expects to submit a U.S. biologics license application as early as year-end 2026, without a specific date. Filing acceptance and approval would be subsequent steps. Beam’s November 10 release.

How much cash and runway does Beam Therapeutics have?

At September 30, 2026, Beam had $1,043.873 million in cash and marketable securities, excluding $6.705 million of restricted cash. The company expects operating coverage into mid-2029, including $200 million in additional borrowing subject to conditions. November 3 runway outlook.

How many BEAM shares are outstanding, and is there dilution risk?

Beam reported 103,495,644 common shares outstanding on October 27, 2026. Options, restricted awards, and pre-funded warrants can add shares over time. No shares were issued under the ATM in the nine months ended September 30; the program still provides capacity. September Form 10-Q.

When did Beam Therapeutics last report earnings?

Beam reported the quarter ended September 30, 2026 on November 3, 2026. Quarterly license and collaboration revenue was $0.307 million and the net loss was $134.405 million, or $1.28 per share. SEC Exhibit 99.1.

What does Beam Therapeutics do?

As of November 21, 2026, Beam was a clinical-stage developer of genetic medicines for inherited disorders. Its lead programs addressed severe sickle cell disease and alpha-1 antitrypsin deficiency. Form 10-Q, operating overview.

What did Beam report in the November 2026 BEACON topline?

On November 10, 2026, Beam said the study met the primary efficacy endpoint, freedom from severe vaso-occlusive crises for at least 12 consecutive months, and all primary safety endpoints at a prespecified interim analysis. Of the 49 treated by October 20, 31 had completed the required follow-up. Beam had not released the detailed pivotal results. Topline announcement.

When does Beam expect the next BEAM-302 milestone?

On November 3, 2026, Beam targeted completing dosing in the global pivotal cohort during the first half of 2027. That window applies to patient dosing, rather than results or a regulatory filing. Company program update.

Primary sources and peer-reviewed clinical literature

Disclaimer. Published by Merlintrader for educational and informational purposes only. It is independent research, not investment advice or legal, tax or medical advice, not an offer or solicitation, and not a research report under applicable United States securities regulation. Nothing here is a recommendation to buy, sell or hold $BEAM or any other security.

Figures come from SEC filings, company releases and market data, with their reference dates; they can change without notice and may be outdated or incomplete when read. Verify every figure against the primary source.

Gene-editing companies carry clinical, regulatory, manufacturing, long-term safety and financing risks. Trial results may not support approval; company milestones may move; safety or efficacy can disappoint. Investors can lose part or all of their capital; each reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.